{
    "clinical_study": {
        "@rank": "95976", 
        "brief_summary": {
            "textblock": "To determine a safe, effective, and convenient dosing schedule for nystatin pastilles in the\n      prevention of oral candidiasis in patients with AIDS or AIDS related complex (ARC) (group\n      III or IV, CDC classification)."
        }, 
        "brief_title": "Nystatin Pastilles for the Prevention of Oral Candidiasis in Patients With AIDS or ARC", 
        "condition": [
            "Candidiasis, Oral", 
            "HIV Infections"
        ], 
        "condition_browse": {
            "mesh_term": [
                "HIV Infections", 
                "Acquired Immunodeficiency Syndrome", 
                "Candidiasis", 
                "Candidiasis, Oral"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n        Concurrent Medication:\n\n        Allowed:\n\n          -  Systemic or oral antibiotics.\n\n          -  Experimental drugs (IND drugs) which are targeted specifically against the AIDS\n             (group IV CDC classification) virus or stimulate the immune system.\n\n        Patients with the following conditions are included:\n\n          -  AIDS or AIDS related complex (ARC) (HIV infection Group 3 or 4, CDC classification)\n             who have had culture-proven oral candidiasis clinically cured within 7 days of study\n             entry and are likely to be compliant for the 20 weeks of nystatin pastille\n             prophylaxis.\n\n          -  Able to follow instructions regarding the use of a pastille.\n\n          -  Patients entering part II of this study (randomized double-blind) must have been\n             clinically cured of oral candidiasis within 1 - 7 days of entry into this randomized\n             study.\n\n          -  Oral lesions such as Kaposi's sarcoma, herpes zoster, and herpes simplex can be\n             enrolled.\n\n        Exclusion Criteria\n\n        Co-existing Condition:\n\n        Patients with the following are excluded:\n\n          -  Systemic candidiasis.\n\n          -  Hypersensitivity to nystatin.\n\n          -  Suspected or proven candidal esophagitis.\n\n        Patients with the following are excluded:\n\n          -  Systemic candidiasis.\n\n          -  Projected survival of less than 6 months.\n\n          -  Unable to maintain a pastille in the buccal cavity for approximately 20 minutes twice\n             a day.\n\n          -  Hypersensitivity to nystatin.\n\n          -  Suspected or proven candidal esophagitis."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "12 Years"
        }, 
        "firstreceived_date": "November 2, 1999", 
        "id_info": {
            "nct_id": "NCT00002057", 
            "org_study_id": "026A", 
            "secondary_id": "4"
        }, 
        "intervention": {
            "intervention_name": "Nystatin", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Nystatin"
        }, 
        "keyword": [
            "Nystatin", 
            "AIDS-Related Opportunistic Infections", 
            "Acquired Immunodeficiency Syndrome", 
            "AIDS-Related Complex", 
            "Candidiasis, Oral"
        ], 
        "lastchanged_date": "October 1, 2007", 
        "link": [
            {
                "description": "BMS Clinical Trials Disclosure", 
                "url": "http://ctr.bms.com/ctd/start.do"
            }, 
            {
                "description": "For FDA Safety Alerts and Recalls refer to the following link www.fda.gov/MEDWATCH/safety.htm", 
                "url": "http://www.fda.gov/MEDWATCH/safety.htm"
            }
        ], 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Birmingham", 
                        "country": "United States", 
                        "state": "Alabama", 
                        "zip": "35233"
                    }, 
                    "name": "Birmingham Veterans Administration Med Ctr / Univ of Alabama"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Princeton", 
                        "country": "United States", 
                        "state": "New Jersey", 
                        "zip": "085434000"
                    }, 
                    "name": "Bristol - Myers Squibb Co"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "Nystatin Pastilles for the Prevention of Oral Candidiasis in Patients With AIDS or ARC", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "N/A", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00002057"
        }, 
        "source": "Bristol-Myers Squibb", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Bristol-Myers Squibb", 
                "agency_class": "Industry"
            }
        }, 
        "study_design": "Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 2007"
    }, 
    "geocoordinates": {
        "Birmingham Veterans Administration Med Ctr / Univ of Alabama": "33.521 -86.802", 
        "Bristol - Myers Squibb Co": "40.366 -74.679"
    }
}